103438-84-2

Usage

Uses

Used in Enantioselective Synthesis:
2-Fluoro-5-hydroxybenzaldehyde is used as a key intermediate in the enantioselective synthesis of 1,1''-spirobiindane-7,7''-diol (SPINOL) derivatives. SPINOL is a versatile chiral ligand widely employed in asymmetric catalysis, which plays a crucial role in the development of enantiomerically pure pharmaceuticals and agrochemicals. The unique properties of 2-fluoro-5-hydroxybenzaldehyde, such as its fluorine substitution and hydroxyl group, contribute to the efficient and selective formation of SPINOL derivatives with desired chiral configurations.

InChI:InChI=1/C7H5FO2/c8-7-2-1-6(10)3-5(7)4-9/h1-4,10H

Upstream product

• 103438-83-1 2-fluoro-5-aminobenzaldehyde dimethyl acetal 
• 2338-54-7 4-fluoro-3-methylanisol 
• 371-41-5 4-Fluorophenol 
• 113984-68-2 4-<(dimethyl-tert-butylsilyl)oxy>fluorobenzene 
• 347176-55-0 4-fluoro-3-dibromomethylanisole 
• 105728-90-3 2-fluoro-5-methoxybenzaldehyde 
• 68-12-2 N,N-dimethyl-formamide 
• 113984-67-1 5-((tert-butyldimethylsilyl)oxy)-2-fluorobenzaldehyde 
• 100-44-7 benzyl chloride 

Downstream Products

• 1000998-64-0 5-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)-2-fluorobenzaldehyde 
• 1000998-70-8 methyl N-(2-fluoro-5-hydroxybenzyl)glycinate 
• 459215-31-7 2-benzoylamino-3-(2-fluoro-5-benzyloxyphenyl)acrylic acid azlactone 
• 459215-41-9 N-benzoyl-3-(2-fluoro-5-hydroxyphenyl)-alanine methyl ester 
• 459215-71-5 N-benzyloxycarbonyl-6-fluoro-meta-tyramine 
• 459215-64-6 (2-fluoro-5-benzyloxyphenyl)acetic acid methyl ester 
• 459215-67-9 2-(5-(benzyloxy)-2-fluorophenyl)acetic acid 
• 459215-57-7 2-(2-fluoro-5-benzyloxyphenyl)-ethylamine 
• 459215-54-4 2-fluoro-5-benzyloxybenzyl cyanide 
• 148613-12-1 3-(2-fluoro-5-hydroxyphenyl)-alanine 
• 459215-46-4 (5-(benzyloxy)-2-fluorophenyl)methano 
• 459215-50-0 2-fluoro-5-benzyloxybenzyl chloride 
• 149029-89-0 2-(2-fluoro-5-hydroxyphenyl)acetic acid 
• 188681-73-4 3-(2-fluoro-5-hydroxy)phenylethyl amine 

Relevant academic research and scientific papers

Desilylation of tert-Butyldimethylsilyl Ethers of Phenols

Treatment of tert-butyldimethylsilyl ethers of phenols and diphenols with potassium fluoride in the presence of catalytic amounts of hydrobromic acid in dimethylformamide generates the corresponding phenols or diphenols in high yields.

Unexpected Regioselectivity in the Lithiation of Fluoroanisoles

The regioselectivity of lithiation of a series of fluoroanisoles and fluoroveratroles has been studied by determining the ratio of isomeric aldehydes produced by dimethylformamide quenching.The position of lithiation is influenced by such factors as temperature and time of the reaction.Contrary to published reports, fluorine competes significantly with the methoxy group as an ortho director in lithiation reactions.Lithiation of dimethyl-tert-butylsilyl ethers of fluorophenols proceeds exclusively ortho to fluorine.

COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS

Provided herein is a compound of formula (XXXII) or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer thereof or a physiologically functional derivative thereof, wherein R1, R2, R3, G, A, E, n, p, and q are defined herein. Also provided herein are compositions comprising a compound of formula (XXXII), and methods of using a compound of formula (XXXII), e.g., in the treatment or prevention of skin disorders.

Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist

BMS-711939 (3) is a potent and selective peroxisome proliferator-activated receptor (PPAR) α agonist, with an EC50 of 4 nM for human PPARα and >1000-fold selectivity vs human PPAR (EC50 = 4.5 μM) and PPAR (EC50 > 100 μM) i

Macrocyclic compounds and methods for their production

There is provided inter alia compounds of formula (I): for use in treatment of viral infection or as an immunosuppressant.

Sanglifehrin Derivatives and Methods for Their Production

There are provided inter alia compounds of formula (I) and (II) and their use in therapy, particularly for the treatment of viral infection.

Novel Dosage Form

There is provided inter alia a pharmaceutical dosage form for oral administration comprising a sanglifehrin as active ingredient in which the sanglifehrin active ingredient is protected from acid degradation in the stomach environment following oral admin

NOVEL DOSAGE FORM

There is provided inter alia apharmaceutical dosage form fororal administration comprising a sanglifehrin as active ingredient in which the sanglifehrin active ingredient is protected from acid degradation in the stomach environment following oral adminis

SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTI-ATHEROSCLEROTIC, ANTI-DYSLIPIDEMIC, ANTI-DIABETIC AND ANTI-OBESITY AGENTS AND METHOD

Compounds are provided which have the structure of Formula (I): wherein R1 is halogen; and X is hydrogen or halogen, and salts thereof, which compounds are useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic, and anti-obesity agent

SUBSTITUTED DIHYDROPYRIDINES AND METHODS OF USE

Compounds are provided that are modulators of the C5a receptor. The compounds are substituted dihydropyridines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of C5a receptors.